Current Opinion in Immunology最新文献_第4页

Can we cure antiphospholipid syndrome? 我们能治愈抗磷脂综合征吗？

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2025-08-06 DOI: 10.1016/j.coi.2025.102610

Pier Luigi Meroni , Enrico Capobianco , Francesco Tedesco

引用次数: 0

Insights and perspectives into the discovery of complement-related biomarkers in cancer 在癌症中发现补体相关生物标志物的见解和观点

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2025-08-06 DOI: 10.1016/j.coi.2025.102633

Daniel Ajona , Janire Debersaques , Ruben Pio

{"title":"Insights and perspectives into the discovery of complement-related biomarkers in cancer","authors":"Daniel Ajona , Janire Debersaques , Ruben Pio","doi":"10.1016/j.coi.2025.102633","DOIUrl":"10.1016/j.coi.2025.102633","url":null,"abstract":"<div><div>The complement system, a central component of innate immunity, is implicated in tumor biology, influencing processes such as tumor progression, immune evasion, and response to therapy. Numerous studies have identified alterations in complement effectors, activation products, regulatory proteins, and receptors in patients with cancer. These findings underscore the potential of complement-derived biomarkers for enhancing cancer diagnosis, prognosis, or treatment guidance across various oncology settings. However, despite substantial progress in discovery and early validation, no complement-related biomarker has yet been integrated into routine oncology practice. Key challenges in the field include the biological complexity of the complement system, variability in testing methods, and the lack of standardized protocols for sample collection, processing, and analysis. Addressing these issues is essential to ensure reliable and reproducible measurements. Moreover, the clinical utility of these biomarkers depends on their validation in real-world settings, as well as their integration with other molecular markers, advanced imaging, radiomics, and artificial intelligence tools. Advancing the development of harmonized assays and reference materials will be critical for the translation of complement biomarkers into clinical use in cancer. This review summarizes current knowledge on complement-related biomarkers in oncology, highlights technical and conceptual challenges, and discusses future directions to fully harness the potential of the complement system in cancer care.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102633"},"PeriodicalIF":5.8,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144779522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Red blood cell alloimmunization immunogenetic risk factor 红细胞异体免疫免疫遗传危险因素

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2025-08-05 DOI: 10.1016/j.coi.2025.102634

Pascal Pedini , Jacques Chiaroni , Christophe Picard

引用次数: 0

The role of epigenetics in inflammatory memory 表观遗传学在炎症记忆中的作用。

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2025-08-04 DOI: 10.1016/j.coi.2025.102630

Yaqin Yu , Yueqi Qiu , Ming Zhao

引用次数: 0

Immunological complications of blood transfusion: current insights and advances 输血的免疫学并发症：当前的见解和进展

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2025-07-29 DOI: 10.1016/j.coi.2025.102617

Naveen Bansal , Manish Raturi , Charu Singh , Yashik Bansal

{"title":"Immunological complications of blood transfusion: current insights and advances","authors":"Naveen Bansal , Manish Raturi , Charu Singh , Yashik Bansal","doi":"10.1016/j.coi.2025.102617","DOIUrl":"10.1016/j.coi.2025.102617","url":null,"abstract":"<div><div>Blood transfusion is integral to modern medicine but carries significant immunological risks. This review outlines key immune-mediated complications, including acute hemolytic transfusion reactions from ABO incompatibility, and febrile nonhemolytic reactions caused by cytokines or antileukocyte antibodies. Other reactions include allergic responses, anaphylaxis (notably in IgA-deficient patients), and transfusion-related acute lung injury — the leading cause of transfusion-related mortality. Delayed hemolytic reactions, alloimmunization-induced platelet refractoriness, transfusion-associated graft-versus-host disease, and post-transfusion purpura also contribute to morbidity. Transfusion-related immunomodulation may increase infection and cancer recurrence risks. Preventive measures such as leukoreduction, irradiation, extended antigen matching, and restrictive transfusion strategies are crucial. This review article emphasis the importance on the need for strict adherence to protocols, enhanced hemovigilance, and education, especially in resource-limited settings. This review article summarizes the various immunological complications of blood transfusion and the recent advances in their etiopathogenesis, prevention, mitigation, and future research direction.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102617"},"PeriodicalIF":5.8,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144721011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can we cure vasculitis? 我们能治愈血管炎吗？

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2025-07-28 DOI: 10.1016/j.coi.2025.102618

Meghan E Free , Dominic J Ciavatta , Ronald J Falk

{"title":"Can we cure vasculitis?","authors":"Meghan E Free , Dominic J Ciavatta , Ronald J Falk","doi":"10.1016/j.coi.2025.102618","DOIUrl":"10.1016/j.coi.2025.102618","url":null,"abstract":"<div><div>As with all autoimmune diseases, antineutrophil cytoplasmic autoantibody (ANCA) vasculitis cannot be cured by a singular approach. This complexity arises because autoimmune conditions typically result from multiple hits to the immune system — including genetic predisposition, environmental exposures, infections, and perturbations in adaptive and innate immunity. However, these multiple hits also offer opportunities to develop targeted, multipronged strategies aimed at achieving lasting remission or even cure. The field of ANCA vasculitis is unique because a subset of patients has successfully discontinued immunosuppression while maintaining remission. This challenges the long-standing belief and paradigm that autoimmunity necessitates lifelong immunosuppression therapy characterized by cycles of relapse and remission. These patients embody the potential for cure. By exploring theoretical pathways — such as early intervention to modulate innate immunity, restoring normal autoantigen production, enhancing immunoregulatory mechanisms, and eliminating autoreactive cells — we can begin to chart a detailed molecular and cellular roadmap. This approach aims to develop combination therapies that restore immune balance and ultimately transform the management of autoimmune vasculitis, moving toward the goal of durable remission and cure.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102618"},"PeriodicalIF":5.8,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144721009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complement system modulation in age-related macular degeneration: navigating failures, building future successes 补体系统调节在年龄相关性黄斑变性：导航失败，建立未来的成功

IF 5.8 2区医学

Current Opinion in Immunology Pub Date : 2025-07-28 DOI: 10.1016/j.coi.2025.102616

Aliénor Vienne-Jumeau , Elodie Bousquet , Francine Behar-Cohen

引用次数: 0

Neuroimmune mechanisms of neuropsychiatric systemic lupus erythematosus 神经精神系统性红斑狼疮的神经免疫机制

IF 6.6 2区医学

Current Opinion in Immunology Pub Date : 2025-07-18 DOI: 10.1016/j.coi.2025.102608

Stacie L Lin , Michael C Carroll

引用次数: 0

Friend or foe? — Janus Langerhans cells in skin immunity and promising clinical application 是敌是友？-朗格汉斯细胞在皮肤免疫中的应用前景

IF 6.6 2区医学

Current Opinion in Immunology Pub Date : 2025-07-18 DOI: 10.1016/j.coi.2025.102615

Mengjiao Chen , Shiyi Yan , Jun Li , Juan Tao

{"title":"Friend or foe? — Janus Langerhans cells in skin immunity and promising clinical application","authors":"Mengjiao Chen , Shiyi Yan , Jun Li , Juan Tao","doi":"10.1016/j.coi.2025.102615","DOIUrl":"10.1016/j.coi.2025.102615","url":null,"abstract":"<div><div>Langerhans cells (LCs), the professional antigen-presenting cells in the epidermis, serve as the first line of defense in the skin's immune system. With advancements in detection technologies and the development of diverse animal models, LCs have been shown to exhibit heterogeneous origins, phenotypes, and functions, which are regulated in a context-dependent manner by various cytokines and transcription factors. This heterogeneity enables LCs to either promote or suppress immune responses depending on the microenvironment. As research advances in elucidating the regulatory mechanisms underlying LC phenotypes and functions across various pathological conditions, clinical studies targeting LCs are gradually progressing. This review summarizes commonly used experimental animal models in LC research, highlights the phenotypic diversity of LCs in various diseases, and discusses their dual roles in disease progression. With our understanding of LC heterogeneity deepening, we anticipate elucidating the characteristic of distinct LC subgroups, thereby establishing a solid foundation for LC-targeted precision immunotherapy.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102615"},"PeriodicalIF":6.6,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144663567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary sclerosing cholangitis: what is new in the therapeutic landscape 原发性硬化性胆管炎：治疗领域的新进展

IF 6.6 2区医学

Current Opinion in Immunology Pub Date : 2025-07-18 DOI: 10.1016/j.coi.2025.102613

Armando Curto , Laura Cristoferi , Marco Carbone , Andrea Galli , Pietro Invernizzi

{"title":"Primary sclerosing cholangitis: what is new in the therapeutic landscape","authors":"Armando Curto , Laura Cristoferi , Marco Carbone , Andrea Galli , Pietro Invernizzi","doi":"10.1016/j.coi.2025.102613","DOIUrl":"10.1016/j.coi.2025.102613","url":null,"abstract":"<div><div>Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease affecting the intra- and extra-hepatic bile ducts, leading to progressive inflammation and fibrosis. Its pathogenesis is complex and involves genetic predisposition, environmental triggers, and their interaction through the gut–liver axis, mediated by the microbiota. To date, no approved therapies modify the natural history of PSC, and liver transplantation remains the only curative option.</div><div>This review provides an overview of current investigational therapies for PSC, emphasizing their mechanisms of action and relevance to the underlying disease biology. It also examines key challenges in therapeutic development, including the lack of validated surrogate end points, clinical heterogeneity, and the confounding effects of concomitant inflammatory bowel disease treatments factors that complicate trial design and interpretation.</div><div>Clarifying these aspects is essential to support the development of effective, targeted therapies for this complex and currently untreatable condition.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"96 ","pages":"Article 102613"},"PeriodicalIF":6.6,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144656225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0